Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study

Table 4 Published studies on the pharmacokinetics of rivaroxaban in patients (mean)

Patients	Demographic information	Age	Dosage	C_max (ng•mL⁻¹)	C_trough (ng•mL^− 1)	CL/F (L•h^− 1)	Vd (L)
Undergoing total hip replacement [17]	Caucasian	27 ~ 93	10 mg qd	124.6^a	9.1^a	7.3	49.1
Deep venous thrombosis [18]	Caucasian	18 ~ 91	20 mg qd	270	25.5	5.67	54.4
Non-valvular atrial fibrillation [19]	Caucasian	51 ~ 92	20 mg qd	290	32	6.1	79.7

ISSN: 2050-6511